Risk of Hospital Readmission Among Adults Aged 50 Years and Older Hospitalized With Respiratory Syncytial Virus (RSV) or Influenza
Author(s)
David Singer, PharmD, MS1, Yan Wang, ScD2, Aozhou Wu, PhD2, Elizabeth La, PhD1, Susan Gerber, MD1, Keith A. Betts, PhD2;
1GSK, Philadelphia, PA, USA, 2Analysis Group, Los Angeles, CA, USA
1GSK, Philadelphia, PA, USA, 2Analysis Group, Los Angeles, CA, USA
Presentation Documents
OBJECTIVES: Evidence suggests that severe RSV disease is associated with adverse health outcomes beyond the acute illness in increased-risk adults. This study aimed to estimate the risk of hospital readmission among adults ≥50 years of age (YOA) hospitalized with RSV or influenza (another vaccine-preventable respiratory virus).
METHODS: Data from Optum’s de-identified Clinformatics® Data Mart Database were analyzed (October 2015-June 2023) in this retrospective cohort study. Adults ≥50 YOA with ≥12 months of continuous enrollment were assigned to cohorts based on RSV or influenza hospitalization (based on ICD‑10 codes; RSV and flu cohorts). Index dates for RSV and flu cohorts were the start of this acute respiratory illness that included hospitalization. Baseline characteristics were measured in the 12 months pre‑index. Risk of hospital readmission was measured for each cohort among those discharged alive from their initial hospitalization, and readmission risk was compared between cohorts using multivariable-adjusted Cox modeling.
RESULTS: In the RSV (n=14,759) and flu (n=77,468) cohorts, mean age was 76.5 and 75.4 years, and mean Charlson comorbidity index was 3.3 and 2.9, respectively. A total of 3,040 patients died during their initial hospitalization and were excluded from readmission analyses. At 30 days, readmission risk was 16.1% (95% confidence interval [CI]: 15.5-16.7%) and 14.4% (95% CI: 14.1-14.6%) for the RSV and flu cohorts, respectively. Three-month readmission risk was 26.1% (95% CI: 25.3-26.8%, RSV cohort) and 23.3% (95% CI: 23.0-23.6%, flu cohort). Thirty-day readmission risks for patients with baseline COPD and heart failure in the RSV cohort were 19.0% and 22.0%, respectively. Readmission risk was not significantly different at 30 days when comparing RSV and flu cohorts.
CONCLUSIONS: Adults ≥50 YOA who experience RSV- or influenza-related hospitalizations are at substantial risk of 30-day and 3-month hospital readmission. These findings further demonstrate the importance of preventing severe RSV and influenza disease in at-risk populations. Funding: GSK (VEO-000616).
METHODS: Data from Optum’s de-identified Clinformatics® Data Mart Database were analyzed (October 2015-June 2023) in this retrospective cohort study. Adults ≥50 YOA with ≥12 months of continuous enrollment were assigned to cohorts based on RSV or influenza hospitalization (based on ICD‑10 codes; RSV and flu cohorts). Index dates for RSV and flu cohorts were the start of this acute respiratory illness that included hospitalization. Baseline characteristics were measured in the 12 months pre‑index. Risk of hospital readmission was measured for each cohort among those discharged alive from their initial hospitalization, and readmission risk was compared between cohorts using multivariable-adjusted Cox modeling.
RESULTS: In the RSV (n=14,759) and flu (n=77,468) cohorts, mean age was 76.5 and 75.4 years, and mean Charlson comorbidity index was 3.3 and 2.9, respectively. A total of 3,040 patients died during their initial hospitalization and were excluded from readmission analyses. At 30 days, readmission risk was 16.1% (95% confidence interval [CI]: 15.5-16.7%) and 14.4% (95% CI: 14.1-14.6%) for the RSV and flu cohorts, respectively. Three-month readmission risk was 26.1% (95% CI: 25.3-26.8%, RSV cohort) and 23.3% (95% CI: 23.0-23.6%, flu cohort). Thirty-day readmission risks for patients with baseline COPD and heart failure in the RSV cohort were 19.0% and 22.0%, respectively. Readmission risk was not significantly different at 30 days when comparing RSV and flu cohorts.
CONCLUSIONS: Adults ≥50 YOA who experience RSV- or influenza-related hospitalizations are at substantial risk of 30-day and 3-month hospital readmission. These findings further demonstrate the importance of preventing severe RSV and influenza disease in at-risk populations. Funding: GSK (VEO-000616).
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE445
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
STA: Vaccines